Remove Allergies Remove Marketing Remove Trial Funding Remove Trials
article thumbnail

Trial backs Lilly’s Olumiant plus remdesivir as combo COVID-19 therapy

pharmaphorum

Adding Eli Lilly’s rheumatoid arthritis drug Olumiant (baricitinib) and Gilead Sciences’ remdesivir reduces recovery time in COVID-19 patients compared to remdesivir alone, says a new trial. The post Trial backs Lilly’s Olumiant plus remdesivir as combo COVID-19 therapy appeared first on.

Trials 110